Evaluation of matrix metalloproteinase-2 and -9 in the cerebrospinal fluid of dogs with intracranial tumors

American Journal of Veterinary Research

Volumn 74, Issue 1, 2013, Pages 122-129

  Mariani, Christopher L ^a   Boozer, Lindsay B ^a,b   Braxton, Alicia M ^a   Platt, Simon R ^b   Vernau, Karen M ^c   McDonnell, John J ^d   Guevar, Julien ^e,f  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e part of Linnaeus veterinary limited   (United Kingdom)

^f Veterinary Practice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; GLUCOCORTICOID;

ARTICLE; CELL COUNT; CEREBROSPINAL FLUID ANALYSIS; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; DOG; ELECTROPHORESIS; ERYTHROCYTE COUNT; GLIOMA; INTRACRANIAL TUMOR; LYMPHOMA; LYMPHOSARCOMA; MENINGIOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; ZYMOGRAPHY;

ANIMALS; BRAIN NEOPLASMS; DOG DISEASES; DOGS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9;

CANIS FAMILIARIS;

EID: 84872075346     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.1.122     Document Type: Article

References (53)

1. Solleveld HA, Bigner DD, Averill DR, et al. Brain tumors in man and animals: report of a workshop. Environ Health Perspect 1986;68:155-173.
2. Snyder JM, Shofer FS, Van Winkle TJ, et al. Canine intracranial primary neoplasia: 173 cases (1986-2003). J Vet Intern Med 2006;20:669-675.
3. Dewey CW, Bahr A, Ducote JM, et al. Primary brain tumors in dogs and cats. Compend Contin Educ Pract Vet 2000;22:756-762.
4. Westworth DR, Dickinson PJ, Vernau W, et al. Choroid plexus tumors in 56 dogs (1985-2007). J Vet Intern Med 2008;22:1157-1165.
5. Sturges BK, Dickinson PJ, Bollen AW, et al. Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs. J Vet Intern Med 2008;22:586-595.
6. Gordon LE, Thacher C, Matthiesen DT, et al. Results of craniotomy for the treatment of cerebral meningioma in 42 cats. Vet Surg 1994;23:94-100.
7. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22-39.
8. Nakaguchi H, Fujimaki T, Matsuno A, et al. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer 1999;85:2249-2254.
9. Patnaik AK, Kay WJ, Hurvitz AI. Intracranial meningioma: a comparative pathologic study of 28 dogs. Vet Pathol 1986;23:369-373.
10. Patnaik AK, Lieberman PH, Erlandson RA, et al. Paranasal meningioma in the dog: a clinicopathologic study of ten cases. Vet Pathol 1986;23:362-368.
11. Greco JJ, Aiken SA, Berg JM, et al. Evaluation of intracranial meningioma resection with a surgical aspirator in dogs: 17 cases (1996-2004). J Am Vet Med Assoc 2006;229:394-400.
12. Klopp LS, Rao S. Endoscopic-assisted intracranial tumor removal in dogs and cats: long-term outcome of 39 cases. J Vet Intern Med 2009;23:108-115.
13. Axlund TW, McGlasson ML, Smith AN. Surgery alone or in combination with radiation therapy for treatment of intracranial meningiomas in dogs: 31 cases (1989-2002). J Am Vet Med Assoc 2002;221:1597-1600.
14. Long S, Argyle DJ, Nixon C, et al. Telomerase reverse transcriptase (TERT) expression and proliferation in canine brain tumours. Neuropathol Appl Neurobiol 2006;32:662-673.
15. Matiasek LA, Platt SR, Adams V, et al. Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs. J Vet Intern Med 2009;23:146-151.
16. Levicar N, Nuttall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir (Wien) 2003;145:825-838.
17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
18. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-540.
19. Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000;61:111-114.
20. Loukopoulos P, Mungall BA, Straw RC, et al. Matrix metalloproteinase-2 and-9 involvement in canine tumors. Vet Pathol 2003;40:382-394.
21. Siddique K, Yanamandra N, Gujrati M, et al. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Int J Oncol 2003;22:289-294.
22. Das A, Tan WL, Smith DR. Expression of extracellular matrix markers in benign meningiomas. Neuropathology 2003;23:275-281.
23. Okada M, Miyake K, Matsumoto Y, et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol 2004;66:29-37.
24. Nordqvist AC, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 2001;95:839-844.
25. Fritz J, Roser F, Tatagiba M, et al. The basement membrane at the tumour-brain interface of brain-invasive grade I meningiomas. Neuropathol Appl Neurobiol 2005;31:339-342.
26. Kinoshita M, Izumoto S, Hashimoto N, et al. Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas. Brain Tumor Pathol 2008;25:73-78.
27. Mandara MT, Pavone S, Mandrioli L, et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in canine and feline meningioma. Vet Pathol 2009;46:836-845.
28. Kos J, Werle B, Lah T, et al. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 2000;15:84-89.
29. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-227.
30. Friedberg MH, Glantz MJ, Klempner MS, et al. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998;82:923-930.
31. Wong ET, Alsop D, Lee D, et al. Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. Cerebrospinal Fluid Res 2008;5:1.
32. Wong ET, Lee D, Tam A, et al. Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis. Clin Lymphoma Myeloma 2007;7:305-308.
33. Bergman RL, Inzana KD, Inzana TJ. Characterization of matrix metalloproteinase-2 and-9 in cerebrospinal fluid of clinically normal dogs. Am J Vet Res 2002;63:1359-1362.
34. Levine JM, Ruaux CG, Bergman RL, et al. Matrix metalloproteinase-9 activity in the cerebrospinal fluid and serum of dogs with acute spinal cord trauma from intervertebral disk disease. Am J Vet Res 2006;67:283-287.
35. Turba ME, Forni M, Gandini G, et al. Recruited leukocytes and local synthesis account for increased matrix metalloproteinase-9 activity in cerebrospinal fluid of dogs with central nervous system neoplasm. J Neurooncol 2007;81:123-129.
36. Lim GP, Backstrom JR, Cullen MJ, et al. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem 1996;67:251-259.
37. Lezin A, Buart S, Smadja D, et al. Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: preferential presence in HTLV type I-infected neurologic patients versus healthy virus carriers. AIDS Res Hum Retroviruses 2000;16:965-972.
38. Maliszewska M, Mader M, Scholl U, et al. Development of an ultrasensitive enzyme immunoassay for the determination of matrix metalloproteinase-9 (MMP-9) levels in normal human cerebrospinal fluid. J Neuroimmunol 2001;116:233-237.
39. Yushchenko M, Weber F, Mader M, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol 2000;110:244-251.
40. Bannikov GA, Karelina TV, Collier IE, et al. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem 2002;277:16022-16027.
41. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
42. Vandevelde M, Spano JS. Cerebrospinal fluid cytology in canine neurologic disease. Am J Vet Res 1977;38:1827-1832.
43. Tzipory L, Vernau KM, Sturges BK, et al. Antemortem diagnosis of localized central nervous system histiocytic sarcoma in 2 dogs. J Vet Intern Med 2009;23:369-374.
44. Tamura S, Tamura Y, Nakamoto Y, et al. MR imaging of histiocytic sarcoma of the canine brain. Vet Radiol Ultrasound 2009;50:178-181.
45. Perides G, Charness ME, Tanner LM, et al. Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis. J Infect Dis 1998;177:401-408.
46. Gijbels K, Masure S, Carton H, et al. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
47. Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. In: Brooks SA, Schumacher U, eds. Methods in molecular medicine: metastasis research protocols. Totowa, NJ: Humana Press, 2001;163-174.
48. Yasumitsu H, Miyazaki K, Umenishi F, et al. Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human schwannoma cells. J Biochem 1992;111:74-80.
49. Rosenberg GA, Dencoff JE, Correa N Jr, et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
50. Liu X, Han Q, Sun R, et al. Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis. Brain Res 2008;1207:237-243.
51. Green JA, Tran CT, Farrar JJ, et al. Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis. PLoS One [serial online] 2009;4:e7277. Available at: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007277;jsessionid=2A ED5F84F63EC458B2B97A4E9E569D5D. Accessed Jun 1, 2009.
52. Wisner ER, Dickinson PJ, Higgins RJ. Magnetic resonance imaging features of canine intracranial neoplasia. Vet Radiol Ultrasound 2011;52:S52-S61.
53. Smith ER, Zurakowski D, Saad A, et al. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008;14:2378-2386.